The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials.
 
Julia Blanter
No Relationships to Disclose
 
Michael Werner
No Relationships to Disclose
 
Melanie Wain Kier
No Relationships to Disclose
 
Olivia Hapanowicz
No Relationships to Disclose
 
Muhieddine Itani
No Relationships to Disclose
 
Maham Ahmad
No Relationships to Disclose
 
Mandy DeMerchant
No Relationships to Disclose
 
Joseph Paul Eder
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Roche Molecular Diagnostics
Consulting or Advisory Role - Atrin Pharmaceuticals; Roche/Genentech
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Ashley Hammad
No Relationships to Disclose
 
Paula King
No Relationships to Disclose
 
Michael Lachowicz
Employment - Arvinas
 
Natalie Lucas
No Relationships to Disclose
 
Thomas Urban Marron
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Gary Shelton
No Relationships to Disclose
 
Kathy Wu
No Relationships to Disclose
 
Suzanne Xu
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Erin Wysong Hofstatter
Employment - GlaxoSmithKline
Leadership - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Deborah Blythe Doroshow
Consulting or Advisory Role - Atheneum; Boston Healthcare Associates; Dedham Group; Guidepoint Global; Mirati Therapeutics; MJH Life Sciences
Other Relationship - Bristol Myers Squibb Foundation; Conquer Cancer Foundation